Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1

Thomas D. Boyer, Arun J. Sanyal, Guadalupe Garcia-Tsao, Frederick Regenstein, Lorenzo Rossaro, Beate Appenrodt, Veit Gülberg, Samuel Sigal, Alice S. Bexon, Peter Teuber

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The development of hepatorenal syndrome type 1 (HRS1) is associated with a poor prognosis. Liver transplantation improves this prognosis, but the degree of the improvement is unclear. Most patients receive vasoconstrictors such as terli-pressin before transplantation, and this may affect the posttransplant outcomes. We examined a cohort of patients with access to liver transplantation from our previously published study of terlipressin plus albumin versus albumin alone in the treatment of HRS1. The purpose of this analysis was the quantification of the survival benefits of liver transplantation for patients with HRS1. Ninety-nine patients were randomized to terlipressin or placebo. Thirty-five patients (35%) received a liver transplant. Among those receiving terlipressin plus albumin, the 180-day survival rates were 100% for transplant patients and 34% for nontransplant patients; among those receiving only albumin, the rates were 94% for transplant patients and 17% for nontransplant patients. The survival rate was significantly better for those achieving a reversal of he-patorenal syndrome (HRS) versus those not achieving a reversal (47% versus 4%, P < 0.001), but it was significantly lower for the responders versus those undergoing liver transplantation (97%). We conclude that the use of terlipressin plus albumin has no significant impact on posttransplant survival. Liver transplantation offers a clear survival benefit to HRS1 patients regardless of the therapy that they receive or the success or failure of HRS reversal. The most likely benefit of terli-pressin in patients undergoing liver transplantation for HRS1 is improved pretransplant renal function, and this should make the posttransplant management of this difficult group of patients easier. For patients not undergoing transplantation, HRS reversal with terlipressin and/or albumin improves survival.

Original languageEnglish (US)
Pages (from-to)1328-1332
Number of pages5
JournalLiver Transplantation
Volume17
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

Hepatorenal Syndrome
Liver Transplantation
Survival
Albumins
Transplants
Survival Rate
Transplantation
Vasoconstrictor Agents

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Hepatology

Cite this

Boyer, T. D., Sanyal, A. J., Garcia-Tsao, G., Regenstein, F., Rossaro, L., Appenrodt, B., ... Teuber, P. (2011). Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transplantation, 17(11), 1328-1332. https://doi.org/10.1002/lt.22395

Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. / Boyer, Thomas D.; Sanyal, Arun J.; Garcia-Tsao, Guadalupe; Regenstein, Frederick; Rossaro, Lorenzo; Appenrodt, Beate; Gülberg, Veit; Sigal, Samuel; Bexon, Alice S.; Teuber, Peter.

In: Liver Transplantation, Vol. 17, No. 11, 11.2011, p. 1328-1332.

Research output: Contribution to journalArticle

Boyer, TD, Sanyal, AJ, Garcia-Tsao, G, Regenstein, F, Rossaro, L, Appenrodt, B, Gülberg, V, Sigal, S, Bexon, AS & Teuber, P 2011, 'Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1', Liver Transplantation, vol. 17, no. 11, pp. 1328-1332. https://doi.org/10.1002/lt.22395
Boyer, Thomas D. ; Sanyal, Arun J. ; Garcia-Tsao, Guadalupe ; Regenstein, Frederick ; Rossaro, Lorenzo ; Appenrodt, Beate ; Gülberg, Veit ; Sigal, Samuel ; Bexon, Alice S. ; Teuber, Peter. / Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. In: Liver Transplantation. 2011 ; Vol. 17, No. 11. pp. 1328-1332.
@article{2dd52eb0d4254ca49002f1edda504a90,
title = "Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1",
abstract = "The development of hepatorenal syndrome type 1 (HRS1) is associated with a poor prognosis. Liver transplantation improves this prognosis, but the degree of the improvement is unclear. Most patients receive vasoconstrictors such as terli-pressin before transplantation, and this may affect the posttransplant outcomes. We examined a cohort of patients with access to liver transplantation from our previously published study of terlipressin plus albumin versus albumin alone in the treatment of HRS1. The purpose of this analysis was the quantification of the survival benefits of liver transplantation for patients with HRS1. Ninety-nine patients were randomized to terlipressin or placebo. Thirty-five patients (35{\%}) received a liver transplant. Among those receiving terlipressin plus albumin, the 180-day survival rates were 100{\%} for transplant patients and 34{\%} for nontransplant patients; among those receiving only albumin, the rates were 94{\%} for transplant patients and 17{\%} for nontransplant patients. The survival rate was significantly better for those achieving a reversal of he-patorenal syndrome (HRS) versus those not achieving a reversal (47{\%} versus 4{\%}, P < 0.001), but it was significantly lower for the responders versus those undergoing liver transplantation (97{\%}). We conclude that the use of terlipressin plus albumin has no significant impact on posttransplant survival. Liver transplantation offers a clear survival benefit to HRS1 patients regardless of the therapy that they receive or the success or failure of HRS reversal. The most likely benefit of terli-pressin in patients undergoing liver transplantation for HRS1 is improved pretransplant renal function, and this should make the posttransplant management of this difficult group of patients easier. For patients not undergoing transplantation, HRS reversal with terlipressin and/or albumin improves survival.",
author = "Boyer, {Thomas D.} and Sanyal, {Arun J.} and Guadalupe Garcia-Tsao and Frederick Regenstein and Lorenzo Rossaro and Beate Appenrodt and Veit G{\"u}lberg and Samuel Sigal and Bexon, {Alice S.} and Peter Teuber",
year = "2011",
month = "11",
doi = "10.1002/lt.22395",
language = "English (US)",
volume = "17",
pages = "1328--1332",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1

AU - Boyer, Thomas D.

AU - Sanyal, Arun J.

AU - Garcia-Tsao, Guadalupe

AU - Regenstein, Frederick

AU - Rossaro, Lorenzo

AU - Appenrodt, Beate

AU - Gülberg, Veit

AU - Sigal, Samuel

AU - Bexon, Alice S.

AU - Teuber, Peter

PY - 2011/11

Y1 - 2011/11

N2 - The development of hepatorenal syndrome type 1 (HRS1) is associated with a poor prognosis. Liver transplantation improves this prognosis, but the degree of the improvement is unclear. Most patients receive vasoconstrictors such as terli-pressin before transplantation, and this may affect the posttransplant outcomes. We examined a cohort of patients with access to liver transplantation from our previously published study of terlipressin plus albumin versus albumin alone in the treatment of HRS1. The purpose of this analysis was the quantification of the survival benefits of liver transplantation for patients with HRS1. Ninety-nine patients were randomized to terlipressin or placebo. Thirty-five patients (35%) received a liver transplant. Among those receiving terlipressin plus albumin, the 180-day survival rates were 100% for transplant patients and 34% for nontransplant patients; among those receiving only albumin, the rates were 94% for transplant patients and 17% for nontransplant patients. The survival rate was significantly better for those achieving a reversal of he-patorenal syndrome (HRS) versus those not achieving a reversal (47% versus 4%, P < 0.001), but it was significantly lower for the responders versus those undergoing liver transplantation (97%). We conclude that the use of terlipressin plus albumin has no significant impact on posttransplant survival. Liver transplantation offers a clear survival benefit to HRS1 patients regardless of the therapy that they receive or the success or failure of HRS reversal. The most likely benefit of terli-pressin in patients undergoing liver transplantation for HRS1 is improved pretransplant renal function, and this should make the posttransplant management of this difficult group of patients easier. For patients not undergoing transplantation, HRS reversal with terlipressin and/or albumin improves survival.

AB - The development of hepatorenal syndrome type 1 (HRS1) is associated with a poor prognosis. Liver transplantation improves this prognosis, but the degree of the improvement is unclear. Most patients receive vasoconstrictors such as terli-pressin before transplantation, and this may affect the posttransplant outcomes. We examined a cohort of patients with access to liver transplantation from our previously published study of terlipressin plus albumin versus albumin alone in the treatment of HRS1. The purpose of this analysis was the quantification of the survival benefits of liver transplantation for patients with HRS1. Ninety-nine patients were randomized to terlipressin or placebo. Thirty-five patients (35%) received a liver transplant. Among those receiving terlipressin plus albumin, the 180-day survival rates were 100% for transplant patients and 34% for nontransplant patients; among those receiving only albumin, the rates were 94% for transplant patients and 17% for nontransplant patients. The survival rate was significantly better for those achieving a reversal of he-patorenal syndrome (HRS) versus those not achieving a reversal (47% versus 4%, P < 0.001), but it was significantly lower for the responders versus those undergoing liver transplantation (97%). We conclude that the use of terlipressin plus albumin has no significant impact on posttransplant survival. Liver transplantation offers a clear survival benefit to HRS1 patients regardless of the therapy that they receive or the success or failure of HRS reversal. The most likely benefit of terli-pressin in patients undergoing liver transplantation for HRS1 is improved pretransplant renal function, and this should make the posttransplant management of this difficult group of patients easier. For patients not undergoing transplantation, HRS reversal with terlipressin and/or albumin improves survival.

UR - http://www.scopus.com/inward/record.url?scp=82955197324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955197324&partnerID=8YFLogxK

U2 - 10.1002/lt.22395

DO - 10.1002/lt.22395

M3 - Article

C2 - 21837734

AN - SCOPUS:82955197324

VL - 17

SP - 1328

EP - 1332

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 11

ER -